InDex Pharmaceuticals Q4’21: Our Comments - Redeye
Redeye leaves its comment on InDex following the announcement of its year-end report. CONCLUDE seems to be developing according to plan; we maintain our positive view on InDex shares.
ANNONS
Redeye leaves its comment on InDex following the announcement of its year-end report. CONCLUDE seems to be developing according to plan; we maintain our positive view on InDex shares.